Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 13,500 shares of common stock to seven new non-executive employees. The RSUs, approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), will vest in equal installments over three years on each anniversary of the grant date, contingent on continued employment. These awards were granted as material inducements for employment and are subject to the Neuronetics 2020 Inducement Plan terms.
Neuronetics (NASDAQ: STIM) ha annunciato l'assegnazione di premi di indennità costituiti da Unità Azionarie Riservate (RSU) che rappresentano 13.500 azioni ordinarie a sette nuovi dipendenti non esecutivi. Le RSU, approvate dal Comitato per la Compensazione dell'azienda ai sensi della Regola di Quotazione NASDAQ 5635(c)(4), matureranno in rate uguali nel corso di tre anni ad ogni anniversario della data di concessione, subordinatamente al mantenimento dell'impiego. Questi premi sono stati concessi come incentivi materiali per l'assunzione e sono soggetti ai termini del Piano di Indennità Neuronetics 2020.
Neuronetics (NASDAQ: STIM) anunció la concesión de premios de incentivo consistentes en Unidades de Acción Restringidas (RSU) que representan 13,500 acciones ordinarias a siete nuevos empleados no ejecutivos. Las RSU, aprobadas por el Comité de Compensación de la compañía bajo la Regla de Listado de NASDAQ 5635(c)(4), se consolidarán en cuotas iguales durante tres años en cada aniversario de la fecha de concesión, siempre que el empleo continúe. Estos premios se otorgaron como incentivos materiales para el empleo y están sujetos a los términos del Plan de Incentivos Neuronetics 2020.
Neuronetics (NASDAQ: STIM)는 비임원 직원 7명에게 13,500주에 해당하는 제한 주식 단위(RSU)로 구성된 유인 상을 부여했다고 발표했습니다. RSU는 NASDAQ 상장 규칙 5635(c)(4)에 따라 회사의 보상 위원회에 의해 승인되었으며, 부여일의 매년 기념일마다 3년에 걸쳐 균등한 할당에 따라 유효하게 됩니다. 이 상은 고용에 대한 물질적 유인으로 부여되었으며 Neuronetics 2020 유인 계획의 조건에 따릅니다.
Neuronetics (NASDAQ: STIM) a annoncé l'octroi de primes d'incitation sous forme d'unités d'actions restreintes (RSU) représentant 13 500 actions ordinaires à sept nouveaux employés non exécutifs. Les RSU, approuvées par le comité de rémunération de l'entreprise conformément à la règle de cotation NASDAQ 5635(c)(4), viendront à expiration en versements égaux sur trois ans à chaque anniversaire de la date d'octroi, sous réserve de maintien de l'emploi. Ces primes ont été accordées en tant qu'incitatifs matériels à l'emploi et sont soumises aux conditions du Plan d'Induction Neuronetics 2020.
Neuronetics (NASDAQ: STIM) gab die Vergabe von Anreizprämien bekannt, die aus eingeschränkten Aktieneinheiten (RSUs) bestehen und 13.500 Stammaktien für sieben neue nicht-executive Mitarbeiter repräsentieren. Die RSUs wurden vom Vergütungsausschuss des Unternehmens gemäß der NASDAQ-Listing-Regel 5635(c)(4) genehmigt und verfallen in gleichen Raten über drei Jahre an jedem Jahrestag des Gewährungsdatums unter der Voraussetzung, dass das Arbeitsverhältnis fortbesteht. Diese Prämien wurden als wesentliche Anreize für die Beschäftigung gewährt und unterliegen den Bedingungen des Neuronetics 2020 Incentive Plans.
- None.
- None.
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 13,500 shares of the Company’s common stock (RSUs) to seven new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 6.9 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID-19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy for Mental Health System to generate revenues; the scale and efficacy of the Company’s salesforce as well as the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy for Mental Health System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
How many shares of RSUs did Neuronetics (STIM) grant in November 2024?
What is the vesting schedule for Neuronetics (STIM) November 2024 RSU grants?
How many new employees received RSU grants from Neuronetics (STIM) in November 2024?
